The most controversial peptide pharmaceutical in America—FDA-approved since 1952, prescribed for infantile spasms and autoimmune flares, and priced at over $38,000 a vial while scientists still debate exactly how it works

ACTH sits at the intersection of three stories: old medicine, new science, and pharmaceutical economics at its most extreme. The hormone was identified in the 1930s, purified in the 1940s, and approved by the FDA in 1952—long before modern clinical trial requirements existed. For decades, it was understood simply as the body's signal to produce cortisol. Prescribe ACTH, stimulate cortisol, reduce inflammation. Straightforward.

Except that explanation has never fully held together. Physicians noticed that ACTH sometimes worked when corticosteroids alone did not—particularly in nephrotic syndrome and certain autoimmune flares. The past two decades of melanocortin research have begun to explain why: ACTH contains the alpha-MSH sequence within its first 13 amino acids, meaning it activates not just MC2R on the adrenal cortex but also MC1R, MC3R, and MC5R on immune cells and kidney podocytes. These non-steroidogenic effects may explain ACTH's therapeutic advantages over cortisol alone.

The pharmaceutical version—H.P. Acthar Gel, a porcine-derived ACTH preparation in a gelatin depot—is manufactured by Mallinckrodt Pharmaceuticals (with rights acquired by ANI Pharmaceuticals). Its price has risen from approximately $40 per vial in 2001 to over $38,000 per vial today. This pricing, combined with the drug's legacy evidence base and aggressive marketing, has generated FTC investigations, congressional scrutiny, and fierce debate over whether Acthar Gel offers meaningful clinical advantages over far cheaper corticosteroid alternatives.

Quick Facts: ACTH at a Glance

What Is ACTH?

Pronunciation: ay-see-tee-AYCH

Your brain is a pharmacy. Every morning, as your body wakes, the anterior pituitary gland cleaves a large precursor protein called POMC and releases a 39-amino acid messenger into the bloodstream: adrenocorticotropic hormone. This messenger travels to the adrenal glands sitting atop each kidney and delivers a single command—make cortisol. Within minutes, cortisol surges, glucose mobilizes, inflammation dials down, and your body is ready to face the day. This is the textbook story of ACTH.

ACTH's first 13 amino acids are identical to alpha-MSH—the master melanocortin peptide. This means ACTH doesn't just talk to adrenal glands. It activates MC1R on macrophages and skin cells, MC3R on neurons and immune cells, and MC5R on exocrine glands. These receptors don't produce cortisol. They suppress NF-κB signaling, reduce pro-inflammatory cytokines, and modulate immune function through pathways that have nothing to do with the adrenal cortex. ACTH is not merely a cortisol trigger—it is a broad-spectrum melanocortin agonist that happens to also stimulate steroid production.

H.P. Acthar Gel is the pharmaceutical version: purified porcine ACTH in a gelatin matrix designed for slow, sustained release after intramuscular or subcutaneous injection. It has been FDA-approved since 1952—predating the Salk polio vaccine—and carries more labeled indications than almost any other biologic in the United States.

Origins and Discovery

The story of ACTH begins in the 1930s, when researchers realized the pituitary gland controlled adrenal function. By 1943, Choh Hao Li and Herbert Evans at UC Berkeley had isolated ACTH from sheep pituitaries. The full 39-amino acid sequence was determined by the early 1950s, making ACTH one of the first peptide hormones fully characterized.

Commercial ACTH preparations appeared rapidly. The FDA approved repository corticotropin injection (Acthar Gel) in 1952 under regulatory standards that would be unrecognizable today—no Phase III RCTs, no placebo-controlled trials required. For decades, ACTH was prescribed as an alternative to cortisone for rheumatic diseases, allergic reactions, and inflammatory conditions. It was unremarkable, inexpensive, and widely available.

The modern ACTH story is primarily an economic one. Questcor Pharmaceuticals acquired the rights to Acthar Gel in 2001 for $100,000 and raised the price from approximately $40 per vial to over $28,000 by 2013. Mallinckrodt acquired Questcor in 2014 for $5.6 billion—largely on Acthar Gel's revenue. The FTC subsequently filed suit alleging Questcor had acquired a competing ACTH product (Synacthen) specifically to prevent competition. Mallinckrodt settled with the FTC for $100 million in 2017. The price has continued rising to over $38,000 per vial.

Meanwhile, the science took a genuinely interesting turn. Research into melanocortin receptors in the 1990s and 2000s revealed that ACTH's anti-inflammatory properties could not be fully explained by adrenal cortisol stimulation. The non-steroidogenic hypothesis—that ACTH provides immunomodulation through direct MCR activation on immune cells—reframed the compound from a simple cortisol trigger to a multi-target melanocortin drug. This hypothesis remains an active area of investigation and may ultimately determine whether Acthar Gel's clinical advantages over corticosteroids are real or marginal.

Mechanism of Action

The Steroidogenic Pathway (Classical)

ACTH binds MC2R on adrenal cortical cells with high affinity. MC2R is unique among melanocortin receptors: it requires MRAP (melanocortin-2 receptor accessory protein) for surface expression and is expressed almost exclusively on the adrenal cortex. Upon binding, MC2R activates adenylyl cyclase → cAMP → PKA → StAR protein upregulation → cholesterol transport into mitochondria → cortisol, corticosterone, and aldosterone synthesis. This is the classical hypothalamic-pituitary-adrenal (HPA) axis: CRH → ACTH → cortisol.

The Non-Steroidogenic Pathway (Melanocortin Immunomodulation)

ACTH 1-13 is structurally identical to α-MSH. This means ACTH activates MC1R (expressed on macrophages, monocytes, dendritic cells, neutrophils, melanocytes, and podocytes), MC3R (neurons, macrophages, gut epithelium), and MC5R (exocrine glands, T lymphocytes). These receptors trigger anti-inflammatory cascades independent of cortisol:

MC1R activation → cAMP elevation → inhibition of NF-κB nuclear translocation → reduced production of TNF-α, IL-1β, IL-6, and IL-8 → increased IL-10 (anti-inflammatory). On renal podocytes, MC1R activation promotes cytoskeletal stabilization through RhoA/Rac1 signaling, potentially explaining ACTH's effects in nephrotic syndrome that corticosteroids alone do not replicate.

MC3R activation → modulation of macrophage efferocytosis (clearance of apoptotic cells) → resolution of inflammation rather than mere suppression. MC5R activation → regulation of sebaceous gland function and T-cell cytokine profiles.

Why This Matters Clinically

If ACTH's benefits were entirely due to cortisol stimulation, there would be no justification for prescribing it over far cheaper corticosteroid tablets. The non-steroidogenic hypothesis provides the only scientifically coherent argument for ACTH's continued clinical relevance—and for Acthar Gel's continued existence. However, definitive proof that MCR-mediated effects provide clinically meaningful advantages over corticosteroids in head-to-head trials remains incomplete.

Key Research Areas and Studies

Infantile Spasms — Standard of Care

The strongest evidence for ACTH is in infantile spasms (West syndrome), a catastrophic pediatric epilepsy syndrome. The 2004 UKISS trial (Lux et al., PMID 15351194) randomized 107 infants: hormonal treatment (ACTH or prednisolone) stopped spasms in 73% versus 54% for vigabatrin (p=0.043). Long-term follow-up showed improved neurodevelopmental outcomes in the hormonal treatment group for cryptogenic spasms. ACTH is considered first-line therapy for infantile spasms in most clinical guidelines, though the optimal dose, duration, and whether ACTH is superior to oral prednisolone remains debated.

Multiple Sclerosis Exacerbations

Rose et al. (1970, PMID 4913764) conducted the landmark trial: 197 patients with acute MS exacerbations randomized to ACTH IM or placebo. ACTH produced significantly faster recovery. This trial, despite its age, remains the basis for ACTH's MS indication. Modern MS treatment has largely moved to IV methylprednisolone for acute relapses, with ACTH reserved as an alternative when IV steroids are impractical or contraindicated.

Nephrotic Syndrome — The MCR Hypothesis in Action

Hogan et al. (2013, PMID 23620400) treated 21 patients with idiopathic membranous nephropathy using Acthar Gel 80 IU SC twice weekly for 12 months. Eleven of 21 (52%) achieved complete or partial remission. The significance: several patients responded who had previously failed corticosteroids—supporting the hypothesis that ACTH's effect on podocytes is mediated through MCR activation, not cortisol. This was a pilot study without a control group, and larger controlled trials have not been completed.

Real-World Evidence Program

Mallinckrodt funded multiple observational studies (2014–present) across approved indications including lupus, rheumatoid arthritis, dermatomyositis, and nephrotic syndrome. These studies generally show clinical improvement, but their design (open-label, no placebo control, industry-funded) limits the strength of the conclusions.

The Pricing Controversy and Scientific Questions

No discussion of ACTH is complete without addressing the central controversy: does H.P. Acthar Gel provide clinical benefits that justify a price exceeding $38,000 per vial, when synthetic ACTH analogs (cosyntropin/Cortrosyn) and direct corticosteroids cost a fraction as much?

The arguments favoring Acthar Gel center on the non-steroidogenic melanocortin mechanism: if ACTH provides immunomodulation through direct MCR activation on immune cells and podocytes, then it is not pharmacologically equivalent to a corticosteroid—and cosyntropin (ACTH 1-24, used diagnostically) has not been studied for therapeutic purposes in the same indications.

The arguments against: Acthar Gel was approved in 1952 under minimal regulatory standards. Many of its 19+ indications were grandfathered rather than proven through modern RCTs. The clinical evidence that ACTH provides meaningful advantages over corticosteroids in head-to-head comparison is thin for most indications. Synthetic ACTH (tetracosactide/Synacthen) is available in other countries at dramatically lower cost but was not marketed in the US after Questcor acquired the rights—an action the FTC challenged as anticompetitive.

Claims vs. Evidence

The Human Evidence Landscape

UKISS — Lux et al., 2004 (PMID 15351194)

Design: Multicenter RCT, N=107 infants with newly diagnosed infantile spasms. Intervention: Hormonal treatment (ACTH or oral prednisolone) vs. vigabatrin. Results: Spasm cessation at day 14: 73% hormonal vs. 54% vigabatrin (p=0.043). Long-term follow-up showed improved neurodevelopmental outcomes for cryptogenic spasms in the hormonal group. Limitations: The trial grouped ACTH and prednisolone together as "hormonal treatment"—the specific superiority of ACTH over prednisolone was not definitively established. US and UK dosing protocols differ.

Rose et al. — MS Exacerbation, 1970 (PMID 4913764)

Design: RCT, N=197 adults with acute MS exacerbation. Intervention: ACTH IM vs. placebo for 2–3 weeks. Results: ACTH produced significantly faster recovery from MS relapses. Limitations: This trial is over 50 years old. Modern MS treatment standards (IV methylprednisolone, disease-modifying therapies) have changed the landscape entirely. No contemporary head-to-head trial of ACTH vs. IV steroids for MS relapse exists.

Hogan et al. — Nephrotic Syndrome, 2013 (PMID 23620400)

Design: Pilot study (open-label), N=21 adults with idiopathic membranous nephropathy, many steroid-refractory. Intervention: Acthar Gel 80 IU SC twice weekly for 12 months. Results: 11/21 (52%) achieved complete or partial remission. Several patients who had failed corticosteroids responded to ACTH. Limitations: No control group. Small sample. Open-label design. The remission rate is promising but cannot be attributed solely to treatment without a comparator arm.

Becker et al. — Historical Review, 2023 (PMID 37792273)

Design: Narrative review. Contribution: Provides historical perspective on ACTH's clinical evolution and the emerging non-steroidogenic melanocortin hypothesis. Not primary evidence but useful for contextualizing the compound's unique position.

Real-World Evidence Studies (Mallinckrodt-funded)

Multiple observational studies across lupus, RA, dermatomyositis, and nephrotic syndrome. Generally positive outcomes reported. All are open-label, uncontrolled, and industry-funded—sufficient to support insurance coverage decisions but not to establish efficacy by modern evidence standards.

Safety, Risks, and Limitations

Adrenal Effects

Prolonged ACTH use causes Cushing syndrome: moon face, central obesity, abdominal striae, glucose intolerance, hypertension, and skin thinning. These effects are dose-dependent and duration-dependent. Abrupt discontinuation after prolonged use causes HPA axis suppression → potential adrenal crisis. Taper protocols are mandatory.

Infection Risk

ACTH-induced immunosuppression increases susceptibility to bacterial, viral, and fungal infections. Latent tuberculosis may reactivate. Live vaccines are contraindicated during treatment.

Metabolic Effects

Hyperglycemia (may precipitate or worsen diabetes). Mineralocorticoid effects from aldosterone stimulation: sodium retention, potassium loss, hypertension, edema.

Bone and Muscle

Long-term use: osteoporosis, vertebral compression fractures, avascular necrosis. Proximal muscle weakness (steroid myopathy).

Psychiatric

Mood changes, insomnia, euphoria, depression, psychosis (rare but documented). Pediatric patients receiving ACTH for infantile spasms require close monitoring for irritability and hypertension.

Pediatric-Specific (Infantile Spasms)

High-dose ACTH in infants carries risks of hypertension, irritability, immunosuppression, and cardiac hypertrophy. Monitoring includes blood pressure, glucose, electrolytes, and infection surveillance. These risks are accepted because infantile spasms carry devastating neurodevelopmental consequences if untreated.

Drug Interactions

ACTH may reduce efficacy of anticoagulants, antidiabetic agents, and antihypertensives. Concurrent use with NSAIDs increases GI ulceration risk. CYP3A4 inducers may alter cortisol metabolism.

Legal and Regulatory Status

FDA Status

ACTH (H.P. Acthar Gel) has been FDA-approved since 1952 for a broad range of indications. Current labeled indications include: infantile spasms, MS exacerbations, nephrotic syndrome (idiopathic or lupus), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus (SLE), dermatomyositis/polymyositis, sarcoidosis, uveitis, serum sickness, and multiple other inflammatory conditions. Many of these indications were grandfathered from the pre-1962 regulatory framework.

WADA Status

PROHIBITED. ACTH is classified under S2—Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Prohibited at all times (in-competition and out-of-competition). Detection: immunoassay of urine samples for exogenous ACTH.

FTC Investigation

The FTC filed suit against Mallinckrodt in 2017, alleging that Questcor's 2013 acquisition of the rights to Synacthen Depot (a competing synthetic ACTH product) was designed to eliminate potential competition for Acthar Gel. Mallinckrodt settled for $100 million and agreed to license Synacthen Depot to a competing manufacturer.

Pricing and Access

Acthar Gel's price trajectory ($40 → $38,000+ per vial) has been the subject of congressional hearings, state attorney general investigations, and insurance coverage disputes. Patient assistance programs and specialty pharmacies partially mitigate cost barriers, but access remains a significant issue.

Research Protocols and Formulation Considerations

Formulation

H.P. Acthar Gel is a repository (depot) formulation: purified porcine ACTH in a gelatin matrix designed for slow absorption after IM or SC injection. The depot formulation provides sustained ACTH release over hours, as opposed to the bolus delivery of synthetic cosyntropin (ACTH 1-24), which is used diagnostically for adrenal function testing (Cortrosyn stimulation test).

Administration

Intramuscular or subcutaneous injection. The gelatin matrix is viscous; proper injection technique matters. Vials require refrigerated storage (2–8°C).

Synthetic Alternatives

Cosyntropin (ACTH 1-24, Cortrosyn) retains the full MCR-binding sequence (the α-MSH fragment is within residues 1-13) and is used for diagnostic purposes but has not been studied therapeutically for Acthar Gel's indications in the US. Tetracosactide (Synacthen Depot) is a synthetic ACTH 1-24 depot formulation used therapeutically in Europe and other regions at a fraction of Acthar Gel's price.

Dosing in Published Research

The following table summarizes dosing protocols for ACTH as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Published Clinical Dosing

Dosing in Self-Experimentation Communities

ACTH (Acthar Gel) has no meaningful presence in self-experimentation or peptide communities. The compound is a prescription pharmaceutical available only through specialty pharmacies, priced at over $38,000 per vial. It is WADA-prohibited and not available from peptide vendors. There is no community dosing protocol to report.

Combination Stacks

Research into ACTH combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining ACTH with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Compound	Type	Evidence Tier	Verdict	Primary Receptor	Primary Mechanism	Primary Application	Human Data	FDA Status	WADA Status	Key Limitation
Alpha-MSH	Endogenous tridecapeptide (13 aa, POMC-derived)	Tier 4 — Preclinical Only	Eyes Open	MC1R (non-selective across MC1/3/4/5)	MC1R → melanogenesis; NF-κB suppression → anti-inflammatory	Pigmentation (endogenous); anti-inflammatory (endogenous)	None therapeutic	Not developed (analogs approved)	Not prohibited	Half-life ~10 min; non-selective; not a drug candidate
Melanotan I	Synthetic linear tridecapeptide α-MSH analog	Tier 2 — Clinical Trials	Reasonable Bet	MC1R	MC1R agonist → eumelanin synthesis (100× potency vs α-MSH)	Photoprotective tanning; precursor to afamelanotide	Phase I (N=83); dose-dependent tanning	Not approved (became afamelanotide)	Not prohibited	Short half-life (~30 min); superseded by afamelanotide depot
Afamelanotide	Synthetic tridecapeptide (16 mg SC implant)	Tier 1 — Approved Drug	Strong Foundation	MC1R	MC1R → eumelanin synthesis + DNA repair enhancement	EPP phototoxicity prevention; vitiligo (Phase II)	Phase III RCT (N=74); long-term N=115; vitiligo N=55	Approved October 2019 (Scenesse) for EPP	Not prohibited	Restricted to EPP (REMS); nevi darkening; melanoma monitoring
Setmelanotide	Synthetic cyclic octapeptide MC4R agonist	Tier 1 — Approved Drug	Strong Foundation	MC4R	MC4R → hypothalamic satiety signaling restoration	Monogenic obesity (POMC/PCSK1/LEPR/BBS deficiency)	Phase 3 (N=21 POMC/LEPR; N=32 BBS; N=18 VENTURE)	Approved November 2020 (IMCIVREE)	Not prohibited	Only works for genetically confirmed MC4R pathway defects; hyperpigmentation (78%)
ACTH	39 aa polypeptide (porcine pituitary, gelatin depot)	Tier 1 — Approved Drug	Reasonable Bet	MC2R (primary); MC1/3/5R (secondary)	MC2R → adrenal cortisol; MCR → immunomodulation	Infantile spasms; MS exacerbation; nephrotic syndrome	RCTs (N=107 IS; N=197 MS); decades of clinical use	Approved 1952 (H.P. Acthar Gel)	Prohibited (S2)	~$38K/vial pricing controversy; limited modern RCTs for most indications
PL-8177	Synthetic selective MC1R agonist (oral formulation)	Tier 2 — Clinical Trials	Reasonable Bet	MC1R	MC1R → anti-inflammatory (NF-κB suppression in gut mucosa)	Ulcerative colitis; IBD	Phase 2 RCT (~N=60; 33% remission vs 0% placebo)	Not approved (Phase 2 complete)	Not prohibited	Phase 3 needed; full data not yet published

Frequently Asked Questions

Summary of Key Findings

ACTH occupies a unique position in medicine: a 70-year-old approved drug whose mechanism is still being rewritten. The steroidogenic pathway—ACTH tells adrenals to make cortisol—is textbook. The non-steroidogenic pathway—ACTH directly modulates immune cells through melanocortin receptors—is the frontier. The first pathway makes ACTH a cortisol trigger. The second may make it something more.

The clinical evidence is strongest for infantile spasms, where ACTH is standard of care based on the UKISS RCT (N=107). For MS exacerbations, the Rose 1970 trial (N=197) established efficacy, but IV methylprednisolone has largely replaced ACTH in modern practice. The nephrotic syndrome pilot (N=21) is the most scientifically provocative—patients who failed steroids responded to ACTH, suggesting melanocortin receptor effects on podocytes—but remains uncontrolled and small. For the majority of Acthar Gel's 19+ approved indications, the evidence predates modern clinical trial standards.

The pricing—over $38,000 per vial for a porcine-derived preparation of a hormone discovered in the 1940s—has generated FTC lawsuits, congressional scrutiny, and legitimate questions about whether the compound's clinical profile justifies its cost. Synthetic ACTH (tetracosactide) is available in other countries at dramatically lower prices but was blocked from the US market through practices the FTC found anticompetitive.

Verdict Recapitulation

ACTH earns Tier 1 on the basis of 70+ years of FDA approval and widespread clinical use. But the Reasonable Bet verdict—rather than Strong Foundation—reflects the gap between ACTH's regulatory status and the depth of its modern evidence base. For infantile spasms, the evidence would support Strong Foundation. For the vast majority of its other indications, the evidence is legacy, observational, or funded by the manufacturer. The non-steroidogenic melanocortin hypothesis is scientifically compelling but not yet proven in the controlled human trials that would convert it from hypothesis to established mechanism.

For readers considering ACTH, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source ACTH

Further Reading and Resources

If you want to go deeper on ACTH, the evidence landscape for tanning & melanocortin peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Tanning & Melanocortin Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: ACTH — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Lux, A. L., et al. (2004). "The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial." The Lancet, 364(9447), 1773–1778. PMID 15351194
2. Rose, A. S., et al. (1970). "Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo." Neurology, 20(5), 1–59. PMID 4913764
3. Hogan, J., et al. (2013). "Treatment of idiopathic membranous nephropathy with adrenocorticotropic hormone gel." American Journal of Nephrology, 38(5), 405–412. PMID 23620400
4. Becker, D. E., et al. (2023). "Adrenocorticotropic hormone: From diagnostic tool to therapeutic agent—a historical and clinical perspective." Clinical Therapeutics, 45(11), e181–e192. PMID 37792273

---